- Home
- TCBP vs ALLR Comparison
TCBP vs ALLR Comparison
Compare TCBP & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBP
- ALLR
- Stock Information
- Founded
- TCBP 2013
- ALLR 2004
- Country
- TCBP United Kingdom
- ALLR United States
- Employees
- TCBP N/A
- ALLR N/A
- Industry
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- TCBP Health Care
- ALLR Health Care
- Exchange
- TCBP Nasdaq
- ALLR Nasdaq
- Market Cap
- TCBP 5.0M
- ALLR 4.7M
- IPO Year
- TCBP 2022
- ALLR N/A
- Fundamental
- Price
- TCBP $0.38
- ALLR $1.05
- Analyst Decision
- TCBP Strong Buy
- ALLR
- Analyst Count
- TCBP 1
- ALLR 0
- Target Price
- TCBP $2.40
- ALLR N/A
- AVG Volume (30 Days)
- TCBP 3.1M
- ALLR 2.6M
- Earning Date
- TCBP 11-25-2024
- ALLR 03-07-2025
- Dividend Yield
- TCBP N/A
- ALLR N/A
- EPS Growth
- TCBP N/A
- ALLR N/A
- EPS
- TCBP N/A
- ALLR N/A
- Revenue
- TCBP N/A
- ALLR N/A
- Revenue This Year
- TCBP N/A
- ALLR N/A
- Revenue Next Year
- TCBP N/A
- ALLR N/A
- P/E Ratio
- TCBP N/A
- ALLR N/A
- Revenue Growth
- TCBP N/A
- ALLR N/A
- 52 Week Low
- TCBP $0.37
- ALLR $0.90
- 52 Week High
- TCBP $32.70
- ALLR $288.00
- Technical
- Relative Strength Index (RSI)
- TCBP 30.77
- ALLR 47.15
- Support Level
- TCBP $0.37
- ALLR $0.96
- Resistance Level
- TCBP $0.47
- ALLR $1.72
- Average True Range (ATR)
- TCBP 0.10
- ALLR 0.17
- MACD
- TCBP 0.01
- ALLR 0.01
- Stochastic Oscillator
- TCBP 2.65
- ALLR 13.99
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.